Headline Expenditure Projections
- Pharmaceuticals : LBP2,056.94bn (US$1.36bn) in 2013 to LBP2,190.07bn (US$1.46bn) in 2014; +6.5% in local currency and +7.3.% in US dollar terms. Forecast broadly in line with Q 2 2014 .
- Healthcare: LBP4,778.68bn (US$3.17bn) in 2013 to LBP5,251.39bn (US$3.51bn) in 2014; +9.9% in local currency and +10.7% US dollar terms. Forecast slightly higher from Q 2 2014 .
For Q3 2014, Lebanon's Pharmaceutical Risk/Reward Rating (RRR) score is calculated at 52.7 out of 100, ranking the country seventh in the Middle East and Africa matrix, one place above last quarter's eighth position.
Key Trends & Developments
The Lebanese Health Minister Wael Abu Faour has announced that prices for another batch of drugs will be reduced by an average of 17%, reports the Daily Star. In March the ministry reduced the prices of 629 medicines by 20%. The decision to reduce prices was approved by all the relevant ministries, including industry, finance, economy and the Shura Council. Abu Faour has warned pharmacies, hospitals, pharmaceutical companies and depots against breaching the decision or objecting to it.
Eisai EMEA has reported that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer...
The Lebanon Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Lebanon Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Lebanese pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Lebanon to test other views - a key input for successful budgeting and strategic business planning in the Lebanese pharmaceutical and healthcare market.
- Target business opportunities and risks in the Lebanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lebanon.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Lebanon benefits from a sizeable healthcare sector where the costs of health services and drug prices are generally high. The private sector accounts for about 90% of Lebanon's hospitals and pharmacies, driving the prescription of high-value pharmaceuticals. However, the government's commitment to cost containment measures continues as it announces further price reductions for an increasing selection of medicines, impacting overall market value. Tension between Lebanese political blocs concerning the ongoing civil war in Syria presents significant risks to both political and economic stability, contributing to factors which impede the market's potential.